ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lundbeck, the Danish drug firm specializing in neurological and brain diseases, has agreed to acquire Charlotte, N.C.-based Chelsea Therapeutics for $530 million up front. The firm will pay Chelsea shareholders an additional $128 million if Chelsea’s FDA-approved Northera meets unspecified commercial milestones by 2017. Northera is a treatment for light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by autonomic failure, a condition associated with Parkinson’s disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter